AKT1 and cancer: By now, only two PI3K inhibitors (idelalisib targeting PI3Kδ and copanlisib targeting Pan-PI3K) and two mTOR inhibitors (temsirolimus targeting mTORC1 and everolimus targeting mTORC1) have been approved by the FDA for the clinical treatment of cancers (150), whereas AKT inhibitors are still in the early phase of clinical tests, and agents that target the AKT E17K mutant appear to be encouraging (151).